1[1]Topalian SL,Muul LM,Solomon D,et al. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods, 1987,102:127～ 134.
2[2]Lawton FG. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced unresected ovarian cancer. Obstet Gynecol, 1989,73: 61.
3[3]Wils J. Primary and delayed debulking surgery and chemotherapy consisting of cisplatin doxorubicin and cyclophosphamide in stage Ⅲ - Ⅳ epithelial ovarian carcinoma. J Clin Oncol, 1986,4 : 1068.
4[4]Hoskins WJ. The influence of cytoreductive surgery on progression free interval and survival in epithelial ovarian cancer. Baillieres Cilnical Gynecol, 1989,3: 59.
5[5]Boente-MP,Chi-DS,Hoskins-WJ. The role of surgery in the management of ovarian cancer ; primary and interval cytoreductive surgery. Semin-Oncol, 1998,25 (3): 326～34.
6[6]Berek - JS, Trope - C, Vergote - I. Surgery during chemotherapy and at relapse of ovarian cancer. Ann- Oncol, 1999,10 Suppl 1: 3 ～
